Stephanie Cragg - Curriculum Vitae#

EDUCATION

• 1993 MA Natural Sciences (Pharmacology), University of Cambridge, UK
  
• 1996 DPhil Pharmacology, University of Oxford, UK

ACADEMIC POSTS and PRIZE FELLOWSHIPS

• 2014 Professor of Neuroscience, University of Oxford, UK
  
• 2006 Tutorial Fellow in Preclinical Medicine, Christ Church, Oxford
  
• 2006 - 2014 Associate Professor in Biomedical Sciences, Oxford
  
• 2004 - 2006 Paton Fellow, Department of Pharmacology, Oxford
  
• 2001 - 2004 Beit Memorial Prize Research Fellowship, Oxford
  
• 1999 - 2002 E.P. Abraham Research Fellowship, Oxford
  
• 1996 - 1999 E.P. Abraham Junior Research Fellowship, Oxford
  
• 1995 - 1999 Visiting Scientist, New York University, and University of North Carolina at Chapel Hill
  
• 1995 - 1998 Mary Goodger Scholarship, University of Oxford

MAJOR CONTRIBUTIONS TO SCIENCE

Published works

1997 - 2006 Somatodendritic dopamine release:

First real-time characterization of somatodendritic release of dopamine from midbrain neurons and regulatory mechanisms (e.g. Cragg et al 1997 J Neurophysiol; Cragg & Greenfield 1997 J Neurosci).

2001 - 2008 Dopamine as a volume transmitter:

Defined the concept of ‘volume’ or extrasynaptic transmission by dopamine (e.g. Cragg et al 2001 J Neurophysiol; Cragg and Rice 2004 Trends Neurosci)

2012 - ongoing Dysregulation of neurotransmission as a prodromal signature of Parkinson’s disease:

In diverse rodent models of Parkinson’s and our work in Oxford Parkinson’s Disease Centre, we established that signatures of dysregulation of neurotransmission precede degeneration (e.g. Janezic et al 2013 PNAS; Roberts et al 2020 Nat Commun) and can be rescued (Brimblecombe et al in review).

2003 - ongoing Axonal integration shapes dopamine function:

Field leaders in identifying circuits and mechanisms in axons that govern dopamine transmission including partner neuromodulators (ACh, GABA, adenosine), ion channels, transporters, Parkinson’s associated proteins, and non-neuronal mechanisms, establishing astrocytes as key partners to striatal circuits (e.g. Cragg 2003 J Neurosci; Rice and Cragg 2004 Nat Neurosci; Zhang et al 2018 Neuron; Condon et al 2019 Nat Commun; Roberts et al 2020 Nat Commun; Stedehouder et al 2024 Nat Commun; Zhang et al 2025 Nat Neurosci).

EXTERNAL LEADERSHIP ROLES (last 10y)

• 2024 - 2026 President, International Society for Monitoring Molecules in Neuroscience (MMiN)
  
• 2025 Editor, The Handbook of Dopamine (Elsevier)
  
• 2022 Founding Member and Inaugural Officer, the Dopamine Society
  
• 2021 Chair, Neuromodulation Theme, ASAP Collaborative Research Network
  
• 2021 Editorial Board Member, Addiction Neuroscience
  
• 2019 - 2024 College of Experts, Parkinson’s UK
  
• 2018 Conference Chair, 17th International Conference for MMiN
  
• 2017 - 2023 Associate Editor, npj Parkinson’s Disease
  
• 2010 - 2021 Co-Founder and Theme Co-Director, Oxford Parkinson’s Disease Centre
  
• 2016 Advisory Board, ACS Chemical Neuroscience
  
• 2015 Editorial Board, npj Parkinson’s Disease